Search

Your search keyword '"Jäger, Ulrich"' showing total 975 results

Search Constraints

Start Over You searched for: Author "Jäger, Ulrich" Remove constraint Author: "Jäger, Ulrich"
975 results on '"Jäger, Ulrich"'

Search Results

3. Narcissistic dimensions and depressive symptoms in patients across mental disorders in cognitive behavioural therapy and in psychoanalytic interactional therapy in Germany: a prospective cohort study

4. Affective temperament, fatigue, and pain in cancer patients

11. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

12. Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

13. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

14. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

16. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

17. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma

18. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

20. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

21. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

22. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL

23. EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

24. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

25. Supplementary Data Figures from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

26. Data from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

27. Supplementary Data Tables from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

28. CT-526 Updated Results From a Rapcabtagene Autoleucel (YTB323) Phase I Study Demonstrate Durable Efficacy and a Manageable Safety Profile in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

29. POSTER: CT-526 Updated Results From a Rapcabtagene Autoleucel (YTB323) Phase I Study Demonstrate Durable Efficacy and a Manageable Safety Profile in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

30. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia

31. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

32. UGT2B17 modifies drug response in chronic lymphocytic leukaemia

33. Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group

34. The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): A representative and useful real-life data source for further biomedical research

35. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia

37. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

38. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

39. CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis

40. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

41. A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells.

42. Risk as a pattern over time: Delineation of time‐dependent risk factors in biological, psychological, and social variables in cancer patients.

43. A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

44. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

46. Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia

47. Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma

48. Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL

49. Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives

50. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study

Catalog

Books, media, physical & digital resources